DANE BEDWARD | EIR
Mr. Dane Bedward is the CEO of NeuroBot Inc., a strategic advisory company focused on assisting Medtech, Digital Medicine and Biopharma companies with their business strategies.
Prior to founding his advisory company, Dane was Senior Vice President International for Genzyme Corporation, one of the top 5 global biotech companies before being acquired by Sanofi-Aventis. His first assignment with Genzyme was as Managing Director and President of the Canadian subsidiary Genzyme Canada Inc. Genzyme Corporation is a pioneer in the development of products for rare genetic diseases.Throughout his career Mr. Bedward has also worked with other organizations such as Nordion International, Johnson and Johnson (in Canada and Europe), Flow Laboratories, and McMaster University.
Dane serves on the Board of Directors of The National Angel Capital Organization (NACO), The Capital Angel Network (CAN), The Ottawa Hospital Research Institute, and Panthera Cryosolutions, as well as chairs the Board of Directors for Spiderwort Inc. He is also a member of the L-Spark MedTech Advisory Committee, an Executive Fellow with Mistral Venture Partners, a Steering Committee member for Alacrity Ottawa, a medical markets strategic advisor for Welch Capital Markets, and a Charter Member of TiE. Dane has previously served on the following Boards: the Board of Governors of the University of Ottawa, the Board of Trustees for Bridgewater State University, The National Medical Devices Alliance, The Ottawa Health and Life Sciences Cluster, The New England-Canada Business Council, The Boston Philharmonic Orchestra, The New England-Latin America Business Council, The Ottawa Life Sciences Council, and the Board of Directors for NeuroBiotech Inc.
Dane is a proud graduate of the University of Ottawa Science program. He has participated as a panel member in numerous conferences globally.
Contact: [email protected]